NCT06152237 - Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 12, 2023

Primary Completion Date

November 2, 2028

Study Completion Date

November 2, 2031

Conditions

Rett Syndrome

Interventions

GENETIC

TSHA-102

TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.

Trial Locations (5)

55101

Gillette Children's Specialty Healthcare, Saint Paul

60612

Rush University Medical Center & Children's Hospital, Chicago

63110

Washington University, St. Louis, St Louis

H3T 1C5

CHU Ste-Justine, Montreal

Unknown

Children's Neurosciences, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London

All Listed Sponsors

lead

Taysha Gene Therapies, Inc.

INDUSTRY